Completion of the Divestment of Aspen’s European Thrombosis Business to Mylan ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/002935/06 Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries (collectively “Aspen” or “the Group”) COMPLETION OF THE DIVESTMENT OF ASPEN’S EUROPEAN THROMBOSIS BUSINESS TO MYLAN Shareholders are referred to the announcement of 8 September 2020 wherein it was confirmed that Aspen Global Incorporated, incorporated in Mauritius, a wholly owned subsidiary of Aspen Holdings, had concluded an agreement in terms whereof Mylan Ireland Limited would acquire the commercialisation rights and related intellectual property in respect of Aspen’s Thrombosis Business in Europe(1)(the “Transaction”). Aspen is pleased to confirm that it has received confirmation that all conditions precedent for the Transaction have now been fulfilled and that the Transaction closed on 27 November 2020. Footnote: (1)Excludes Russia and the other Commonwealth of Independent States countries. Durban 02 December 2020 Sponsor Investec Bank Limited Date: 02-12-2020 09:00:00 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.